Back to Top

The Vortex Biosciences mission is to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives.

We are in the midst of a paradigm shift in how cancer can be diagnosed and treated. The combination of targeted therapies and precise diagnostics is allowing for the era of personalized medicine to emerge. The capture and enrichment of circulating tumor cells is going to be a critical element of targeted companion diagnostics. We believe our next generation CTC capture system will allow the full diagnostic potential of CTCs to finally be realized.

Management & Board

François Martelet, MD

Chairman of the Board

François Martelet, Chief Executive Officer, joined NetScientific in 2015.

He brings over 20 years of biopharma experience and a proven track record of shaping and developing businesses to deliver returns. He has broad experience in both large and small companies, deep knowledge of commercialisation and has proven managerial capabilities.

Previously, François served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

Prior to this, François served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.

François gained a Doctorate in Medicine and a Master’s Degree in Business from Dijon University, and holds a Degree in Legal Medicine from R. Descartes University School of Medicine, Paris. He is also a graduate of the Advanced General Management Program at INSEAD.

François Martelet’s awards include the Pasteur Institute medal (1989) and the Knight of the French National Order Merit (2011).

Dino Di Carlo, PhD

Scientific Advisor

Dino Di Carlo is Professor in the Department of Bioengineering at the University of California, Los Angeles (UCLA) where he directs the Microfluidic Biotechnology Laboratory. He is also a co-director of the Life Photonics Laboratory, a member of the California NanoSystems Institute (CNSI), and a member of the Jonsson Comprehensive Cancer Center – Cancer Nanotechnology Program Area. Dino received his B.S. in Bioengineering from the University of California, Berkeley in 2002 and received a Ph.D in Bioengineering from the University of California, Berkeley and San Francisco in 2006. He then conducted postdoctoral studies from 2006-2008 at the Center for Engineering in Medicine at Harvard Medical School and Massachusetts General Hospital. Professor Di Carlo has also received numerous academic honors including the U.S. National Science Foundation (NSF) Early CAREER Award, Office of Naval Research (ONR) Young Investigator Award, Packard Fellowship, Defense Advanced Research Projects Agency (DARPA) Young Faculty Award, National Institutes of Health (NIH) Director’s New Innovator Award, and Coulter Translational Research Award.

Professor Di Carlo has pioneered the use of fluid inertia for precision control of cells and particles and developed fundamental new methods of measuring cell physical properties and applying these measures to diagnose disease. Heis an inventor and continues to innovate around the core Vortex technology for filter-less and high-throughput collection of large cells from bodily fluids. As an engineer, inventor and entrepreneur, Professor Di Carlo founded, serves on the scientific advisory boards, or advises several early-stage companies including CytoVale, Ruubix, and Vortex Biosciences.

Jonathan Goldman, M.D

Scientific Advisor

Jonathan Goldman, M.D., is the Director of Clinical Trials in Thoracic Oncology and the Associate Director of Drug Development at UCLA Health. He completed his residency at UCSF and his fellowship in Hematology/Oncology at UCLA. His research focuses on cancer drug development with an emphasis on treatment for thoracic malignancies. In his role as the Director of Clinical Trials, he is working to develop novel anti-cancer drugs that have been identified in the lab and investigate their toxicity and efficacy with patients in the clinic. He is working on a diversity of projects on both targeted and immune therapies with Eli Lilly, Bristol Meyers Squibb, Astra Zeneca/MedImmune, and Roche/Genentech. Clinically, he cares for patients with many types of cancer, with a particular focus on treating lung cancer. He is always looking for new approaches to improve the efficiency of clinical trials. In collaboration with other departments, he has developed novel laboratory and radiographic techniques to aid in both patient stratification and patient monitoring. He received his degree from Harvard University and his M.D. from Stanford Medical School.

Massimo Cristofanilli, M.D

Scientific Advisor

Massimo Cristofanilli, MD, an expert in the translational research and treatment of patients with inflammatory breast cancer (IBC), is the Associate Director for Translational Research and Precision Medicine and Professor of Medicine in the Division of Hematology & Oncology at the Robert H Lurie Comprehensive Cancer Center, Northwestern University-Feinberg School of Medicine. Dr. Cristofanilli has led the development of novel diagnostic and prognostic markers in primary and metastatic breast cancer. His paper in the New England Journal of Medicine opened up the liquid biopsy field showing the prognostic importance of CTCs in breast cancer with the CellSearch system. In his research and academic role he is focused on advancing a patient-centered, biology driven model of cancer care; combining sophisticated tissue and blood-based molecular diagnostic technologies and innovative treatments. Prior to joining the Lurie Cancer Center, Dr. Cristofanilli was Director of the Breast Care Center and Deputy Director for Translational Research at the Sidney Kimmel Cancer Center at Thomas Jefferson University. He previously served as Chair of the Department of Medical Oncology at Fox Chase Cancer Center, and Executive Director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic at the University of Texas MD Anderson Cancer Center.

Stanley Frankel, M.D

Scientific Advisor

Stanley Frankel, M.D., is an internationally recognized expert in the treatment of hematologic malignancies including ALL and lymphoma. He is currently the Corporate Vice President, Head of Immuno-oncology, Clinical Research and Development at Celgene. Through 2014 he served as Executive Director, Medical Sciences; Early Development, Oncology Therapeutic Area Head at Amgen. Among his primary responsibilities at Amgen were the clinical development of bispecific T cell engaging antibody constructs (BiTE®s) including blinatumomab. Prior experience includes roles as Vice President, Clinical Develoment at Micromet, Clinical Director and Clinical Science Leader at Hoffman-LaRoche; Executive Director for US External Scientific Affairs and Senior Director, Clinical Research at Merck. Dr. Frankel chaired the Zolinza Product Development Team and led the clinical efforts for the successful approval of Zolinza in 2006. From 2001-2004, he was Director, Medical Operations, at Genta, Inc working on Genasense. Prior to joining Genta, Dr. Frankel was Clinical Associate Professor of Medicine at the University of Maryland in Baltimore Greenebaum Cancer Center. He was previously on the faculty at Roswell Park Cancer Institute in Buffalo, NY and the Lombardi Cancer Center at Georgetown University. In addition to his contributions to the approval of Blincyto and Zolinza, Dr. Frankel worked as an academic investigator on the development of 11 other approved oncology drugs including Vesanoid and Trisenox for acute promyelocytic leukemia, Rituxan, Zevalin, Bexxar for CD20 expressing malignancies, Neulasta, Kepivance, Mylotarg, and Gleevec.

Elodie Sollier Christen, PhD

Chief Scientific Officer, Vice-President Research & Development

Elodie is Co-Founder, Chief Scientific Officer and Vice-President Research & Development for Vortex Biosciences, heading the initiatives for the commercialization of microfluidic devices for cancer research and diagnostics.

Elodie received a Physics Engineering Degree from Grenoble Institute of Technology and a PhD in Physics for Life Science from CEA LETI Minatec at Grenoble, France. Her PhD was followed by post-doctoral research in Bioengineering Department, University of California, Los Angeles, with Professor Dino Di Carlo. Her work resulted in the publication of articles in peer-reviewed journals, review papers, presentations in international conferences, and several patents including technologies licensed to Vortex Biosciences from UCLA.

Elodie’s expertise includes the development of new microfluidic devices for biological applications, focusing especially on blood sample preparation and analysis. She has been investigating different microfabrication approaches for transitioning from laboratory research to commercialization.

Gene Walther

CEO & Board Member

Gene Walther is a senior executive with over 20 years of experience in the for-profit and global health segments focusing on diagnostics, medical devices and biotechnology. Gene was consulting to the Paul G. Allen Family Foundation on their Ebola Strategy with a particular focus on the role of diagnostics. Most recently, Gene worked at the Bill & Melinda Gates Foundation as the Deputy Director of Diagnostics. Prior to joining the Gates Foundation, Gene worked in a number of for-profit companies including the venture capital industry where he served as Executive Chairman for GenturaDx.

Mr. Walther was President of Chiron’s Blood Testing Division prior to the acquisition by Novartis in 2006 and then President of Novartis Diagnostics. Prior to joining Chiron/Novartis Mr. Walther was Vice President of Sales & Marketing for Gen-Probe, and various positions at Abbott Diagnostics Division and American Hospital Supply Corporation (later acquired by Baxter).

Mr. Walther earned a BS degree in immunology and microbiology from Michigan State University and a MBA from the Foster School of Business at the University of Washington.

Ernest Schneider

Legal, Secretary & Board Member

Ernest Schneider is an English solicitor (attorney), patent & trade mark attorney and accredited mediator. He is the Commercial-Legal Director and Company Secretary of NetScientific plc and joined the Vortex Board in January 2016.

He was a partner with two large London law firms after which he established a successful international niche intellectual property firm. Ernest has negotiated and drafted numerous technology cross-license, joint venture and M&A agreements. He has masterminded, put in place and maintained a worldwide licensing programme with hundreds of combines patent, trademark and know-how license agreements. He has enforced, defended and challenged intellectual property rights around the world, conducting litigation, arbitration and mediation in most countries in Europe and in the USA, Canada, Hong Kong, Australia and New Zealand. Interwoven with his legal practice, Ernest has held executive and non-executive directorships and chairmanships in industry. He also has personal entrepreneurial experience, having set up and shut down a couple of business ventures of his own.

Ernest grew up in Lancaster, Florida and Luxembourg where he took his baccalauréat in sciences. He obtained his first degree in economics from Lancaster University Management School and then read law and postgraduate EU law at Leeds Business School. He is fluent in French, German and Lëtzebuergesch, has fluent but colloquial Hungarian and useful intermediate Spanish.

Steve Crouse

Chief Commercial Officer

Steve Crouse is the Chief Commercial Officer, responsible for all commercial operations at Vortex Biosciences including sales, marketing and support. Steve is a seasoned executive with >15 years of experience leading marketing and sales organizations in Life Science and Biotechnology companies. Most recently, Steve was the SVP of Sales and Marketing at Freeslate, Inc., leading global commercial operations. Steve helped transition the Freeslate business model from a custom automation business to a successful life science product business that was ultimately acquired by Unchained Labs in February 2016. Prior to joining Freeslate, Steve held several marketing, sales, and R&D leadership roles with Bio-Rad Laboratories and Life Technologies (now ThermoFisher). In these roles he led strategic planning and product development teams, was responsible for OEM and Out-licensing sales, and ran operations for a new R&D Center in Shanghai, China. He has a MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University.

Tarhan Kayihan

Director of Quality

Tarhan is the Director of Quality for Vortex Biosciences.

Tarhan has provided Quality and Regulatory leadership in the medical device/life science industries for over a decade, working with Class I, II, and III devices. He has successfully led QA/RA teams, developed Quality Management Systems, and guided product development at global and Bay Area companies including Stryker, Thermo Fisher Scientific, Conceptus (Bayer Healthcare), and AliveCor.

Tarhan has prior experience in manufacturing engineering and project management. Tarhan has a BS in Industrial Engineering from the University of Washington.

Deborah Neff

Board Member

Ms. Neff has served in a number of leadership positions in healthcare companies, including a 15-year career at Becton Dickinson & Co in executive management positions, making her ideally positioned to provide oversight to Vortex Biosciences. During her time at Becton Dickinson & Co, she was the Worldwide President of BD Biosciences with global P&L responsibilities. Under her leadership, the BD Biosciences grew to be a ~$700M business. Most recently, Deborah was the Chief Operating Officer of Complete Genomics Inc., where she led strategy development, established and delivered financial and operational milestones, and was responsible for operations, commercial and product development. Prior to that she was the President and Chief Executive Officer at both Predicant Biosciences Inc, and at Pathwork Diagnostics Inc., where she led the raising of capital, hiring of the executive team, development of an FDA cleared product, and achieved multi-million dollar annual sales. She was a member of the Board of Directors at Advanced Medical Optics Inc. and ForteBio Corporation Inc. prior to their being acquired, and is currently a member of the Board of Directors at Bio-Rad Laboratories.

Robert F. Englert

CTO & Vice-President of Manufacturing

Robert Englert is a Medical Device and Life Sciences executive with 25 years of global experience in IVD, Point of Care and digital health. Previously Bob was CEO and Founder of Biomedtrics Inc., a diabetes data management company where he raised funding and commercialized a mobile medical data device. Prior to that he was COO of Pelikan Technologies, a Point of Care glucose testing company. Earlier in his career Bob held multiple senior roles at Abbott Laboratories, including Business Unit Manager for Thyroid, Metabolic and Cardiovascular Diseases, Technical Support Director and Director of Operations. Bob has worked and lived in the U.S., Europe and Asia. In his various career roles, he has been responsible for the R&D, engineering, manufacturing and launch of numerous products across a spectrum of technologies including IVD immunoassays, Point of Care and digital health wireless devices. Bob received a Bachelor of Science Degree in Biology from the University of Illinois Urbana-Champaign.

Ian Postlethwaite

Board Member

Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016.
He brings over 14 years of biopharma experience and a proven track record of driving revenue growth and funding development programs. He has broad experience in both private and public companies; from start-ups to multi-nationals.

He was previously an Executive Director on the board of Allergy Therapeutics Plc. He joined Allergy in April 2002 as Finance Director whilst it was private company, initially performing a financial turnaround and then listing it two years later in 2004 on the AIM of the London Stock Exchange. Revenue increased from £12 to c.£49m over his tenure and he raised £107m through equity issues and €40m through debt finance to fund over 15 clinical studies.

Prior to this he worked for Ellerman Investments (1997-2002), a UK private equity house, undertaking the roles of Chief Executive Officer with AFS, which was one of the largest independent finance houses in the UK, raising over £400m in debt finance, and Finance Director with a number of successful start-up technology companies. Previously he held senior finance positions with Ericsson and Philips Electronics.

He is also a non-executive director and Deputy Chairman of Shoreham Port. He is a Fellow of the Chartered Association of Certified Accountants and has a BSc (Hons) in Geological Sciences from Aston University.

François Martelet, MD

Chairman of the Board

Gene Walther

CEO & Board Member

Ernest Schneider

Legal, Secretary & Board Member

Deborah Neff

Board Member

Ian Postlethwaite

Board Member

Tarhan Kayihan

Director of Quality

Elodie Sollier Christen, PhD

CSO & VP R&D

Steve Crouse

CCO

Robert F. Englert

CTO & VP Manufacturing

Scientific Advisors

Dino Di Carlo, PhD

Jonathan Goldman, M.D

Massimo Cristofanilli, M.D

Stanley Frankel, M.D

 

Investors

Vortex Biosciences Inc, is a core subsidiary of NetScientific plc, a transatlantic biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at http://www.netscientific.net

 

Careers

Vortex Biosciences, Inc. is looking for dynamic individuals with expertise in cell and molecular biology, microfluidics, and commercialization of medical devices.

Openings may be available in other areas as the company expands. So, if you are interested in an entrepreneurial role with opportunity for growth, if you are passionate about new technologies for improving overall health, if you want to be a part of unlocking the challenges of early cancer detection, we encourage you to contact us.

For more information or to apply, fill out the form provided or email us at careers@vortexbiosciences.com.

SEND
 
Attach Resume/CV
 

Marketing Communication Specialist

Marketing Communication Specialist

We have a great product that is ready to change the way cancer is diagnosed and treated. Now we need someone who can help us get the message out. The Marketing Communication Specialist will be responsible for executing a global marketing communication strategy that raises awareness to the great products Vortex Biosciences offers. The Marketing Communications Specialist is responsible for the execution of all marketing communications including eblasts, webinars, events, content creation, press releases and any other external communication. The position will require effective managing of a range of critical tasks while maintaining high quality work.

Specific Duties

  • Execute strategic external communications that enhance the Vortex Bioscience brand within the targeted markets
  • Execute demand generation activities in conjunction with product management, which is designed to support the Vortex lead generation goals.
  • Manage a process for incoming leads, ensuring leads are properly managed and nurtured to maximize conversion rates.
  • Partner with product management to develop and maintain marketing collateral/assets including: brochures, white papers, customer case studies, videos, ROI studies and calculators, webinars, etc.
  • Manage content creation on the company website.
  • Work with the product managers to write and develop email blast campaigns including buying lists and managing the production of email blast
  • Work with stake holders in the organization to write press releases and ensure they have visibility in the marketplace
  • Oversee the corporate brand and messaging, ensuring its consistency throughout all outbound materials. Measure and manage brand penetration to ensure expected proliferation.
  • Coordinate trade show participation including booth design and setup, event sponsorships and other strategies to ensure show success.
  • Manage and coordinate outside agencies as needed.

Qualifications:

  • Experience in working with product managers to develop and deliver great content.
  • Demonstrated ability to take ownership of responsibilities, overcome obstacles, deliver on commitments, and delight the customer.
  • Bachelor’s degree required.
  • 1-3 years marketing communication experience preferably in a life science company
  • Dynamic and confident personality with the ability to work independently and to successfully drive projects with minimal guidance.
  • Must be able to multi-task, function effectively under strict deadlines and time constraints, schedule workload to meet deadlines and be able to manage time efficiently in a fast-paced environment.
  • A creative thinker with excellent written and verbal communication skills.
  • Ability to work effectively with cross-functional teams.
  • Prior experience with salesforce.com and automated marketing preferred.

Senior Electrical Engineer, Full-time.

Senior Electrical Engineer

Specific Duties
• Instrument development and testing: The employee will play a key role in the development and testing of the electrical, firmware and software design of the CTC instrument.
• Field service support: The employee will support field service through troubleshooting functionality and performance issues, resolving these and proposing solutions and design improvements.
• Reports: Document results in weekly update reports. Present & discuss designs and results in group meetings. Generate test protocols and perform design verification testing.
• Support to management: Help to manage the lab space and maintenance of related equipment.

Qualifications
• Strong candidate working within multidisciplinary team of scientists, cell and molecular biologists, mechanical and electrical engineers to improve a state-of-the-art sample preparation system for cancer diagnostic applications.
• The candidate should have a M.S. in Electrical Engineering or related fields, with hands-on experience in electrical board design (schematic capture, layout, soldering), test and measurement equipment (oscilloscope, logic analyzer), object-oriented programming (C++, C#, or Java).
• Industry experience in R&D for medical devices is a plus.
• The ideal candidate would be familiar with microfluidic technologies and have previous experience in medical device design, development, and verification. Experience with microfluidic sensors and actuators, optical sensors, and signal processing is a plus.
• The candidate is expected to be thorough, systematic, organized, follow procedures, pay attention to details, be able to work independently and must be motivated to work with a team in a fast paced start-up environment.
• Candidate will also work with team by executing comprehensive design/verification studies and generating associated deliverables such as data analysis, reports and experimental data conclusions.
• The Candidate must be legally authorized to work in the USA.

 
'; } ?>